- Author
- Year
- 2015
- Title
- Post-authorisation assessment of orphan drugs
- Journal
- Lancet
- Volume | Issue number
- 386 | 10007
- Pages (from-to)
- 1940-1941
- Document type
- Article
- Faculty
- Faculty of Social and Behavioural Sciences (FMG)
Faculty of Medicine (AMC-UvA) - Institute
- Amsterdam Institute for Social Science Research (AISSR)
- Abstract
-
The EU regulation of orphan drugs has promoted the development of new treatments for rare disorders.1 However, the high cost of most orphan drugs threatens the sustainability of public health care. Unfortunately, the effectiveness of treatment is often unclear for part, if not all, of the patient population, especially for patients with very rare diseases, such as inherited metabolic disorders. We believe that the system of post-authorisation assessment for orphan drugs needs to be reformed to address these problems.
- URL
- go to publisher's site
- Language
- English
- Persistent Identifier
- https://hdl.handle.net/11245/1.497610
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library, or send a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.